Autolus Therapeutics (AUTL) Net Cash Flow (2017 - 2025)
Autolus Therapeutics' Net Cash Flow history spans 6 years, with the latest figure at $17.4 million for Q4 2025.
- For Q4 2025, Net Cash Flow rose 104.45% year-over-year to $17.4 million; the TTM value through Dec 2025 reached -$129.4 million, down 1048.72%, while the annual FY2025 figure was -$129.4 million, 1048.72% down from the prior year.
- Net Cash Flow reached $17.4 million in Q4 2025 per AUTL's latest filing, up from -$34.1 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $520.4 million in Q1 2024 to a low of -$391.5 million in Q4 2024.
- Average Net Cash Flow over 4 years is -$6.9 million, with a median of -$41.7 million recorded in 2023.
- The largest YoY upside for Net Cash Flow was 1213.57% in 2024 against a maximum downside of 1389.39% in 2024.
- A 4-year view of Net Cash Flow shows it stood at $208.3 million in 2022, then tumbled by 112.62% to -$26.3 million in 2023, then tumbled by 1389.39% to -$391.5 million in 2024, then soared by 104.45% to $17.4 million in 2025.
- Per Business Quant, the three most recent readings for AUTL's Net Cash Flow are $17.4 million (Q4 2025), -$34.1 million (Q3 2025), and $22.4 million (Q2 2025).